Bimekizumab for Psoriasis

Recruiting at 1 trial location

Overseen By Jerry Bagel

Age: 18+

Sex: Any

Trial Phase: Phase 4

Sponsor: Icahn School of Medicine at Mount Sinai

Must not be taking: Corticosteroids, JAK inhibitors

Disqualifiers: HIV, Hepatitis, IBD, others

No Placebo Group All trial participants will receive the active study treatment (no placebo)

Prior Safety Data This treatment has passed at least one previous human trial

Approved in 2 Jurisdictions This treatment is already approved in other countries

Compensation: Varies

Number of Visits: 7

Duration: 16 weeks

60 Participants Needed

What You Need to Know Before You Apply

What is the purpose of this trial?

This trial tests a treatment called bimekizumab for individuals with moderate-to-severe psoriasis. The goal is to evaluate the effectiveness and safety of bimekizumab for those who haven't found success with other similar treatments. Bimekizumab targets interleukins, substances in the body that can cause inflammation and worsen psoriasis. This trial is for individuals whose psoriasis treatments targeting interleukins IL-17A or 23 were ineffective. Suitable candidates are those who have tried these treatments for at least three months without improvement. As a Phase 4 trial, bimekizumab has already received FDA approval and proven effective, and this research aims to understand how it benefits more patients.

Will I have to stop taking my current medications?

The trial requires that you stop using certain medications before starting, such as systemic non-biologic psoriasis therapies and topical corticosteroids, for a specific period before the baseline visit. It's best to discuss your current medications with the trial team to see if any need to be paused.

What is the safety track record for bimekizumab?

Research has shown that bimekizumab is consistently safe for treating moderate-to-severe plaque psoriasis. Studies have found that people generally tolerate the treatment well, with no new safety concerns over time. Reports indicate that side effects tend to remain stable or even decrease with prolonged use. Additionally, the approval of bimekizumab for treating psoriasis further supports its safety in humans. For those considering joining this trial, these findings suggest that bimekizumab is generally safe for most patients. ^{1 2 3 4 5}

Why are researchers enthusiastic about this study treatment?

Bimekizumab is unique because it targets both IL-17A and IL-17F, whereas most current psoriasis treatments, like secukinumab and ixekizumab, target only IL-17A. By inhibiting both of these inflammatory cytokines, Bimekizumab may offer improved efficacy for individuals who haven't responded well to existing therapies. Researchers are excited because this dual action could provide better skin clearance and longer-lasting results for people with moderate-to-severe psoriasis.

What is the effectiveness track record for bimekizumab in treating psoriasis?

Research has shown that bimekizumab, the treatment under study in this trial, effectively treats moderate-to-severe psoriasis. It targets specific proteins in the body called interleukins, which cause inflammation. One study found that almost two-thirds of patients achieved completely clear skin and maintained it for several years. Other research supports this, showing long-lasting improvement for up to five years. Bimekizumab has cleared skin more effectively than other treatments in the same category, making it a promising option, especially for those who haven't had success with similar therapies. ^{6 7 8 9 10}

Who Is on the Research Team?

Mark Lebwohl, MD

Principal Investigator

Ichan School of Medicine

Are You a Good Fit for This Trial?

This trial is for individuals with moderate-to-severe plaque psoriasis who haven't had success with therapies targeting interleukin IL-17A or 23. Participants should have a history of treatment failure and be in need of an alternative.

Inclusion Criteria

Participant has a BSA score of >3 prior to randomization

Participant is able to provide written informed consent and comply with the requirements of this study protocol

Participant is judged to be in good general health as determined by the principal investigator

Exclusion Criteria

History of suicide attempt, or are clinically judged by investigator to be at risk of suicide

Clinically important deviation as judged by the investigator (such WBC< 3) from normal limits in physical examination, vital sign measurements, clinical laboratory tests results, and not associated with a chronic, well-controlled medical condition

I have not had a heart attack or stroke in the last 6 months.

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

1 visit (in-person)

Treatment

Participants receive bimekizumab 320 mg via subcutaneous injection at weeks 0, 4, 8, 12, and 16. Evaluations include change in PGA, PASI score, BSA, and adverse events.

16 weeks

5 visits (in-person)

Follow-up

Participants are monitored for safety and effectiveness after treatment

4 weeks

1 visit (in-person)

What Are the Treatments Tested in This Trial?

Interventions

• Bimekizumab

Trial Overview The study tests bimekizumab's effectiveness and safety in treating psoriasis. Bimekizumab works by blocking substances called interleukins (IL-17A and IL-17F) to reduce inflammation associated with the condition.

How Is the Trial Designed?

Group I: Individuals with moderate-to-severe psoriasis Experimental Treatment 1 Intervention

Individuals with moderate-to-severe psoriasis who have failed similar therapies.

Bimekizumab is already approved in European Union, United States for the following indications:

Approved in European Union as Bimzelx for:

• Moderate to severe plaque psoriasis
• Active psoriatic arthritis
• Non-radiographic axial spondyloarthritis
• Active ankylosing spondylitis

Approved in United States as Bimzelx for:

• Moderate-to-severe plaque psoriasis
• Active psoriatic arthritis
• Non-radiographic axial spondyloarthritis
• Active ankylosing spondylitis
• Hidradenitis suppurativa

Who Is Running the Clinical Trial?

Icahn School of Medicine at Mount Sinai

Lead Sponsor

Trials

933

Recruited

579,000+

UCB Pharma

Industry Sponsor

Trials

345

Recruited

110,000+

Jean-Christophe Tellier

UCB Pharma

Chief Executive Officer since 2015

MD specialized in Rheumatology

Prof. Dr. Iris Löw-Friedrich

UCB Pharma

Chief Medical Officer since 2004

MD, PhD

Psoriasis Treatment Center of Central New Jersey

Collaborator

Trials

18

Recruited

530+

Published Research Related to This Trial

Bimekizumab demonstrated superior efficacy compared to secukinumab in achieving complete skin clearance (PASI 100) in patients with moderate to severe plaque psoriasis, with 74.8% of patients achieving this at Week 48 compared to 52.8% for secukinumab.

The high rates of skin clearance achieved with bimekizumab were maintained through Week 96, and patients switching from secukinumab to bimekizumab also experienced significant improvements, indicating its effectiveness over a 2-year period.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Bimekizumab efficacy and safety in patients with moderate to severe plaque psoriasis: Two-year interim results from the open-label extension of the randomized BE RADIANT phase 3b trial. Strober, B., Paul, C., Blauvelt, A., et al.[2023]

In a phase 3b trial involving 743 patients with moderate-to-severe plaque psoriasis, bimekizumab demonstrated superior efficacy compared to secukinumab, with 61.7% achieving complete skin clearance (PASI 100) at week 16 versus 48.9% for secukinumab.

While bimekizumab showed greater skin clearance over 48 weeks, it was associated with a higher incidence of oral candidiasis (19.3% vs. 3.0% for secukinumab), indicating a need for monitoring this side effect in patients.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Bimekizumab versus Secukinumab in Plaque Psoriasis. Reich, K., Warren, RB., Lebwohl, M., et al.[2021]

Bimekizumab, a new monoclonal antibody that targets IL-17A and IL-17F, has been shown to be effective in treating moderate to severe plaque psoriasis, achieving significant improvements (PASI90 and PASI100) as early as week 4 and maintaining these results for up to 52 weeks.

In Phase III clinical trials, bimekizumab demonstrated a faster onset of action and greater efficacy compared to other treatments like adalimumab, ustekinumab, and secukinumab, while maintaining a comparable safety profile.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Bimekizumab for the Treatment of Psoriasis: A Review of the Current Knowledge. Ruggiero, A., Potestio, L., Camela, E., et al.[2022]

In a phase 3 trial involving 435 patients with moderate to severe plaque psoriasis, bimekizumab demonstrated significant efficacy, with 91% of patients achieving a 90% improvement in psoriasis severity (PASI90) at week 16 compared to only 1% in the placebo group.

Bimekizumab was well tolerated over 56 weeks, with no unexpected safety issues, and maintained high response rates with both every 4-week and every 8-week dosing schedules.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Bimekizumab efficacy and safety in moderate to severe plaque psoriasis (BE READY): a multicentre, double-blind, placebo-controlled, randomised withdrawal phase 3 trial. Gordon, KB., Foley, P., Krueger, JG., et al.[2021]

In a phase 3 trial involving 567 patients with moderate to severe plaque psoriasis, bimekizumab demonstrated significantly higher efficacy than both ustekinumab and placebo, with 85% of patients achieving a 90% improvement in psoriasis severity (PASI90) at week 16.

The safety profile of bimekizumab was consistent with previous studies, with serious treatment-emergent adverse events reported in 6% of patients, indicating it is a safe option for treating psoriasis.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Bimekizumab versus ustekinumab for the treatment of moderate to severe plaque psoriasis (BE VIVID): efficacy and safety from a 52-week, multicentre, double-blind, active comparator and placebo controlled phase 3 trial. Reich, K., Papp, KA., Blauvelt, A., et al.[2021]

Bimekizumab (BKZ) demonstrated sustained efficacy in treating active psoriatic arthritis (PsA) from Week 16 to Week 52, maintaining significant improvements in ACR response criteria and psoriasis severity measures.

The treatment was well tolerated, with a similar rate of treatment-emergent adverse events (TEAEs) compared to adalimumab, and no new safety concerns were identified, although localized Candida infections were noted in a small percentage of patients.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Bimekizumab treatment in biologic DMARD-naïve patients with active psoriatic arthritis: 52-week efficacy and safety results from the phase III, randomised, placebo-controlled, active reference BE OPTIMAL study. Ritchlin, CT., Coates, LC., McInnes, IB., et al.[2023]

Bimekizumab is significantly more effective than placebo and active comparators in treating moderate-to-severe plaque psoriasis, showing rapid onset of action with clinically meaningful responses observed as early as 4 weeks after the first dose.

The safety profile of bimekizumab is comparable to that of active comparators, with similar rates of adverse events, although oral candidiasis was noted as a common side effect.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Bimekizumab for the treatment of moderate-to-severe plaque psoriasis: a meta-analysis of randomized clinical trials. Wang, Y., Li, S., Bai, J., et al.[2023]

Bimekizumab, a monoclonal antibody targeting IL-17A and IL-17F, showed significant efficacy in treating moderate-to-severe plaque psoriasis, with 57% of patients achieving complete skin clearance (PASI 100) by week 12 after treatment.

The treatment led to rapid normalization of skin-related gene expressions associated with psoriasis, indicating a profound biological response, which supports further investigation of maintenance dosing every 4 or 8 weeks in future studies.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Bimekizumab for the treatment of moderate-to-severe plaque psoriasis: efficacy, safety, pharmacokinetics, pharmacodynamics and transcriptomics from a phase IIa, randomized, double-blind multicentre study. Oliver, R., Krueger, JG., Glatt, S., et al.[2022]

Ixekizumab, a monoclonal antibody targeting IL-17A, has shown superior efficacy compared to etanercept and ustekinumab in treating moderate-to-severe plaque psoriasis, and comparable efficacy to adalimumab in psoriatic arthritis, based on long-term Phase III studies.

The safety profile of ixekizumab is generally tolerable, similar to other biologics, but requires monitoring for non-invasive Candida infections and caution in patients with inflammatory bowel disease due to potential exacerbations.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Ixekizumab for the treatment of psoriasis: an update on new data since first approval. Blegvad, C., Skov, L., Zachariae, C.[2020]

Citations

1. ucb.com ucb.com/newsroom/press-releases/article/bimzelxrv-bimekizumab-data-in-moderate-to-severe-plaque-psoriasis-at-eadv-showed-four-year-sustained-remission-and-potential-to-reduce-psoriatic-arthritis-progression-risk

BIMZELX[®][▼] (bimekizumab) data in moderate-to-severe ... BIMZELX[®][▽] (bimekizumab) data in moderate-to-severe plaque psoriasis at EADV showed four-year sustained remission, and potential to reduce ...

2. pubmed.ncbi.nlm.nih.gov pubmed.ncbi.nlm.nih.gov/39862230/

Bimekizumab efficacy and safety through 3 years in ... Bimekizumab has previously shown superior achievement of complete skin clearance [100% improvement from baseline in Psoriasis Area and Severity ...

3. ucb.com ucb.com/newsroom/press-releases/article/bimzelxr-bimekizumab-bkzx-five-year-data-at-aad-2025-showed-sustained-skin-clearance-and-long-term-efficacy-in-moderate-to-severe-plaque-psoriasis

BIMZELX[®] (bimekizumab-bkzx) five-year data at AAD ... BIMZELX[®] (bimekizumab-bkzx) five-year data at AAD 2025 showed sustained skin clearance and long-term efficacy in moderate-to-severe plaque psoriasis.

4. jaad.org jaad.org/article/S0190-9622(25)00668-1/fulltext

Bimekizumab durability of efficacy through 196 weeks and ... Almost two-thirds of bimekizumab-treated patients achieved and maintained complete skin clearance through 196 weeks, and safety data were ...

5. ucbcompass.com ucbcompass.com/sites/default/files/2024-10/EADV24_4-Year%20HIA_submitted.pdf

Bimekizumab 4-year efficacy in high-impact areas in ... Bimekizumab 4-year efficacy in high-impact areas in moderate to severe plaque psoriasis: Pooled results from BE BRIGHT. Table 1. Baseline characteristics.

6. bimzelxhcp.com bimzelxhcp.com/HS/Safety

Consistent safety profile across PSO and HS 1,2 BIMZELX® testing exhibited no new safety signals in one year: it was well tolerated by patients with HS. See short-term and long-term testing data for BIMZELX®.

7. ucb.com ucb.com/newsroom/press-releases/article/ucb-presents-new-4-year-data-for-bimzelxrvbimekizumab-in-moderate-to-severe-plaque-psoriasis-at-eadv-2024

UCB presents new 4-year data for BIMZELX ... Data showed that treatment-emergent adverse events were consistent or decreased with longer bimekizumab exposure, with no new safety signals.

8. ucb-usa.com ucb-usa.com/stories-media/UCB-U-S-News/detail/article/bimzelxr-bimekizumab-bkzx-five-year-data-at-aad-2025-showed-sustained-skin-clearance-and-long-term-efficacy-in-moderate-to-severe-plaque-psoriasis

BIMZELX® (bimekizumab-bkzx) Five-Year Data at AAD ... Bimekizumab efficacy and safety in moderate-to-severe plaque psoriasis (BE READY): a multicentre, double-blind, placebo-controlled ...

9. bimzelx.com bimzelx.com/plaque-psoriasis/about-bimzelx/side-effects

Safety and Side Effects | BIMZELX® (bimekizumab‐bkzx) Learn about common and serious side effects and what to share with your doctor before starting BIMZELX® plaque psoriasis treatment.

10. pubmed.ncbi.nlm.nih.gov pubmed.ncbi.nlm.nih.gov/37950894/

Bimekizumab safety in patients with moderate-to-severe ... Bimekizumab safety in patients with moderate-to-severe plaque psoriasis: pooled data from up to 3 years of treatment in randomized phase III ...